Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334958 · ClinicalTrials.gov registry record · Phase 3
Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures
A Phase 3 study of Epilepsy, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 356
- Enrollment target
- 20
- Study locations
NCT00334958 is a Phase 3 study of Epilepsy that has completed, run by Eisai. The registered enrollment target is 356 participants, below the 950-participant average among 160 other Epilepsy trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00334958, a Phase 3 study of Epilepsy, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 356 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rufinamide
Study Locations (20)
Florida
- Bradenton Research Center - Bradenton
- University of Florida, Dept. of Neurology - Gainesville
- University of Florida, The Neuroscience Institute at Shands - Jacksonville
- Pediatric Neurologists of Palm Beach - Loxahatchee Groves
- Nemours Children's Clinic - Orlando
- Pediatric Neurology - PA - Orlando
- Bay Medical Center - Panama City
- University of Southern Florida, Dept. of Neurology - Tampa
Arizona
- Barrow Neurological Institute - Phoenix
- Mayo Clinic Epilepsy and Neurology - Phoenix
- University of Arizona, Dept. of Neurology - Tucson
California
- Neuro-Pain Medical Center, Inc. - Fresno
- Neurology Center - Oceanside
- California Pacific Epilepsy - San Francisco
Alabama
- University of South Alabama Medical Center - Mobile
- Neurology Clinic PC - Northport
District of Columbia
- Georgetown University Hospital, Dept. of Neurology - Washington D.C.
- Children's National Medical Center - Washington D.C.
Arkansas
- Clinical Trials, Inc - Little Rock
Georgia
- Child Neurology Associates, PC - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2006-02-13 |
| Est. Completion | 2009-05-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00334958
The ClinicalTrials.gov registry entry for NCT00334958 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 950-participant average among 160 other Epilepsy trials with a reported enrollment target (63% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00334958 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00334958 about?
NCT00334958 is a clinical study titled "Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures". To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs).
What is the current status of trial NCT00334958?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 356 participants. The study started on 2006-02-13. Estimated completion is 2009-05-20.
What conditions does trial NCT00334958 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00334958?
The interventions under investigation include: Placebo (DRUG), Rufinamide (DRUG).
Who is sponsoring clinical trial NCT00334958?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00334958 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.